A Randomized, Double-Blind, Phase 2 Study of Perioperative MK-4280A (Coformulation of Favezelimab and Pembrolizumab) vs Pembrolizumab in Patients With Resectable Cutaneous Squamous Cell Carcinoma
Titel:
A Randomized, Double-Blind, Phase 2 Study of Perioperative MK-4280A (Coformulation of Favezelimab and Pembrolizumab) vs Pembrolizumab in Patients With Resectable Cutaneous Squamous Cell Carcinoma
Auteur:
Schadendorf, D. Koyfman, S. Silk, A.W. Davar, D. Clark, J. Ladwa, R. Lee, J. Suttner, L.H. Groisberg, R. Jin, F. Hanna, G.